Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1046 entries
Sorted by: Best Match Show Resources per page
Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections.

Infection and drug resistance

Falci DR, Pasqualotto AC.
PMID: 24187505
Infect Drug Resist. 2013 Oct 22;6:163-74. doi: 10.2147/IDR.S51340.

The triazole class of antifungal drugs comprises first-line agents for the treatment of several invasive fungal diseases. Isavuconazole is a novel broad-spectrum triazole agent. Here we summarize its characteristics and compare it with the currently available antifungal agents. Isavuconazole...

Cite
Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist. 2013;6:163-74doi: 10.2147/IDR.S51340.
Falci, D. R., & Pasqualotto, A. C. (2013). Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infection and drug resistance, 6163-74. https://doi.org/10.2147/IDR.S51340
Falci, Diego R, and Pasqualotto, Alessandro C. "Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections." Infection and drug resistance vol. 6 (2013): 163-74. doi: https://doi.org/10.2147/IDR.S51340
Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist. 2013 Oct 22;6:163-74. doi: 10.2147/IDR.S51340. PMID: 24187505; PMCID: PMC3810441.
Copy Download .nbib Format: NLM
Role of isavuconazole in the treatment of invasive fungal infections.

Therapeutics and clinical risk management

Wilson DT, Dimondi VP, Johnson SW, Jones TM, Drew RH.
PMID: 27536124
Ther Clin Risk Manag. 2016 Aug 03;12:1197-206. doi: 10.2147/TCRM.S90335. eCollection 2016.

Despite recent advances in both diagnosis and prevention, the incidence of invasive fungal infections continues to rise. Available antifungal agents to treat invasive fungal infections include polyenes, triazoles, and echinocandins. Unfortunately, individual agents within each class may be limited...

Cite
Wilson DT, Dimondi VP, Johnson SW, et al. Role of isavuconazole in the treatment of invasive fungal infections. Ther Clin Risk Manag. 2016;12:1197-206doi: 10.2147/TCRM.S90335.
Wilson, D. T., Dimondi, V. P., Johnson, S. W., Jones, T. M., & Drew, R. H. (2016). Role of isavuconazole in the treatment of invasive fungal infections. Therapeutics and clinical risk management, 121197-206. https://doi.org/10.2147/TCRM.S90335
Wilson, Dustin T, et al. "Role of isavuconazole in the treatment of invasive fungal infections." Therapeutics and clinical risk management vol. 12 (2016): 1197-206. doi: https://doi.org/10.2147/TCRM.S90335
Wilson DT, Dimondi VP, Johnson SW, Jones TM, Drew RH. Role of isavuconazole in the treatment of invasive fungal infections. Ther Clin Risk Manag. 2016 Aug 03;12:1197-206. doi: 10.2147/TCRM.S90335. eCollection 2016. PMID: 27536124; PMCID: PMC4977098.
Copy Download .nbib Format: NLM
Transcriptomics Analysis of Candida albicans Treated with Huanglian Jiedu Decoction Using RNA-seq.

Evidence-based complementary and alternative medicine : eCAM

Yang Q, Gao L, Tao M, Chen Z, Yang X, Cao Y.
PMID: 27143984
Evid Based Complement Alternat Med. 2016;2016:3198249. doi: 10.1155/2016/3198249. Epub 2016 Apr 06.

Candida albicans is the major invasive fungal pathogen of humans, causing diseases ranging from superficial mucosal infections to disseminated, systemic infections that are often life-threatening. Resistance of C. albicans to antifungal agents and limited antifungal agents has potentially serious...

Cite
Yang Q, Gao L, Tao M, et al. Transcriptomics Analysis of Candida albicans Treated with Huanglian Jiedu Decoction Using RNA-seq. Evid Based Complement Alternat Med. 2016;2016:3198249doi: 10.1155/2016/3198249.
Yang, Q., Gao, L., Tao, M., Chen, Z., Yang, X., & Cao, Y. (2016). Transcriptomics Analysis of Candida albicans Treated with Huanglian Jiedu Decoction Using RNA-seq. Evidence-based complementary and alternative medicine : eCAM, 20163198249. https://doi.org/10.1155/2016/3198249
Yang, Qianqian, et al. "Transcriptomics Analysis of Candida albicans Treated with Huanglian Jiedu Decoction Using RNA-seq." Evidence-based complementary and alternative medicine : eCAM vol. 2016 (2016): 3198249. doi: https://doi.org/10.1155/2016/3198249
Yang Q, Gao L, Tao M, Chen Z, Yang X, Cao Y. Transcriptomics Analysis of Candida albicans Treated with Huanglian Jiedu Decoction Using RNA-seq. Evid Based Complement Alternat Med. 2016;2016:3198249. doi: 10.1155/2016/3198249. Epub 2016 Apr 06. PMID: 27143984; PMCID: PMC4837275.
Copy Download .nbib Format: NLM
Invasive candidiasis in non neutropenic critically ill - need for region-specific management guidelines.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine

Ahmed A, Azim A, Baronia AK, Marak RS, Gurjar M.
PMID: 26195859
Indian J Crit Care Med. 2015 Jun;19(6):333-9. doi: 10.4103/0972-5229.158273.

Use of antifungal agents has increased over past few decades. A number of risk factors such as immunosuppression, broad spectrum antibiotics, dialysis, pancreatitis, surgery, etc., have been linked with the increased risk of invasive candidiasis. Though there are various...

Cite
Ahmed A, Azim A, Baronia AK, et al. Invasive candidiasis in non neutropenic critically ill - need for region-specific management guidelines. Indian J Crit Care Med. 2015;19(6):333-9doi: 10.4103/0972-5229.158273.
Ahmed, A., Azim, A., Baronia, A. K., Marak, R. S., & Gurjar, M. (2015). Invasive candidiasis in non neutropenic critically ill - need for region-specific management guidelines. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine, 19(6), 333-9. https://doi.org/10.4103/0972-5229.158273
Ahmed, Armin, et al. "Invasive candidiasis in non neutropenic critically ill - need for region-specific management guidelines." Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine vol. 19,6 (2015): 333-9. doi: https://doi.org/10.4103/0972-5229.158273
Ahmed A, Azim A, Baronia AK, Marak RS, Gurjar M. Invasive candidiasis in non neutropenic critically ill - need for region-specific management guidelines. Indian J Crit Care Med. 2015 Jun;19(6):333-9. doi: 10.4103/0972-5229.158273. PMID: 26195859; PMCID: PMC4478674.
Copy Download .nbib Format: NLM
Investigation of In Vitro Activity of Five Antifungal Drugs against Dermatophytes Species Isolated from Clinical Samples Using the E-Test Method.

The Eurasian journal of medicine

Aktas AE, Yigit N, Aktas A, Gozubuyuk SG.
PMID: 25610290
Eurasian J Med. 2014 Feb;46(1):26-31. doi: 10.5152/eajm.2014.05.

OBJECTIVE: Dermatomycosis is an infection with fungi related to the skin: glabrous skin, hair and/or nails. Oral treatment of fungal infections in dermatology has become a preferred modality for the management of these very common conditions. Although there are...

Cite
Aktas AE, Yigit N, Aktas A, et al. Investigation of In Vitro Activity of Five Antifungal Drugs against Dermatophytes Species Isolated from Clinical Samples Using the E-Test Method. Eurasian J Med. 2014;46(1):26-31doi: 10.5152/eajm.2014.05.
Aktas, A. E., Yigit, N., Aktas, A., & Gozubuyuk, S. G. (2014). Investigation of In Vitro Activity of Five Antifungal Drugs against Dermatophytes Species Isolated from Clinical Samples Using the E-Test Method. The Eurasian journal of medicine, 46(1), 26-31. https://doi.org/10.5152/eajm.2014.05
Aktas, Ayse Esin, et al. "Investigation of In Vitro Activity of Five Antifungal Drugs against Dermatophytes Species Isolated from Clinical Samples Using the E-Test Method." The Eurasian journal of medicine vol. 46,1 (2014): 26-31. doi: https://doi.org/10.5152/eajm.2014.05
Aktas AE, Yigit N, Aktas A, Gozubuyuk SG. Investigation of In Vitro Activity of Five Antifungal Drugs against Dermatophytes Species Isolated from Clinical Samples Using the E-Test Method. Eurasian J Med. 2014 Feb;46(1):26-31. doi: 10.5152/eajm.2014.05. PMID: 25610290; PMCID: PMC4261438.
Copy Download .nbib Format: NLM
Management of invasive candidiasis in nonneutropenic ICU patients.

Therapeutic advances in infectious disease

Weiss E, Timsit JF.
PMID: 25745560
Ther Adv Infect Dis. 2014 Oct;2(5):105-15. doi: 10.1177/2049936114562586.

Invasive candidiasis (IC) is a leading cause of morbidity and mortality among nonneutropenic ICU patients and these life-threatening nosocomial infections require early diagnosis and prompt treatment. However, none of the predictive tools are sufficiently accurate to identify high-risk patients...

Cite
Weiss E, Timsit JF. Management of invasive candidiasis in nonneutropenic ICU patients. Ther Adv Infect Dis. 2014;2(5):105-15doi: 10.1177/2049936114562586.
Weiss, E., & Timsit, J. F. (2014). Management of invasive candidiasis in nonneutropenic ICU patients. Therapeutic advances in infectious disease, 2(5), 105-15. https://doi.org/10.1177/2049936114562586
Weiss, Emmanuel, and Timsit, Jean-François. "Management of invasive candidiasis in nonneutropenic ICU patients." Therapeutic advances in infectious disease vol. 2,5 (2014): 105-15. doi: https://doi.org/10.1177/2049936114562586
Weiss E, Timsit JF. Management of invasive candidiasis in nonneutropenic ICU patients. Ther Adv Infect Dis. 2014 Oct;2(5):105-15. doi: 10.1177/2049936114562586. PMID: 25745560; PMCID: PMC4340669.
Copy Download .nbib Format: NLM
Essential Oils and Antifungal Activity.

Pharmaceuticals (Basel, Switzerland)

Nazzaro F, Fratianni F, Coppola R, Feo V.
PMID: 29099084
Pharmaceuticals (Basel). 2017 Nov 02;10(4). doi: 10.3390/ph10040086.

Since ancient times, folk medicine and agro-food science have benefitted from the use of plant derivatives, such as essential oils, to combat different diseases, as well as to preserve food. In Nature, essential oils play a fundamental role in...

Cite
Nazzaro F, Fratianni F, Coppola R, et al. Essential Oils and Antifungal Activity. Pharmaceuticals (Basel). 2017;10(4)doi: 10.3390/ph10040086.
Nazzaro, F., Fratianni, F., Coppola, R., & Feo, V. (2017). Essential Oils and Antifungal Activity. Pharmaceuticals (Basel, Switzerland), 10(4), . https://doi.org/10.3390/ph10040086
Nazzaro, Filomena, et al. "Essential Oils and Antifungal Activity." Pharmaceuticals (Basel, Switzerland) vol. 10,4 (2017). doi: https://doi.org/10.3390/ph10040086
Nazzaro F, Fratianni F, Coppola R, Feo V. Essential Oils and Antifungal Activity. Pharmaceuticals (Basel). 2017 Nov 02;10(4). doi: 10.3390/ph10040086. PMID: 29099084; PMCID: PMC5748643.
Copy Download .nbib Format: NLM
Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia.

Blood research

Lee KH, Lim YT, Hah JO, Kim YK, Lee CH, Lee JM.
PMID: 29043231
Blood Res. 2017 Sep;52(3):167-173. doi: 10.5045/br.2017.52.3.167. Epub 2017 Sep 25.

BACKGROUND: Invasive fungal infections (IFIs) are a life-threatening problem in immunocompromised patients. Despite timely diagnosis and appropriate antifungal therapy, clinical outcomes of IFIs remain unsatisfactory, necessitating treatment with a combination of antifungal agents. Therefore, childhood leukemic patients treated with...

Cite
Lee KH, Lim YT, Hah JO, et al. Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia. Blood Res. 2017;52(3):167-173doi: 10.5045/br.2017.52.3.167.
Lee, K. H., Lim, Y. T., Hah, J. O., Kim, Y. K., Lee, C. H., & Lee, J. M. (2017). Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia. Blood research, 52(3), 167-173. https://doi.org/10.5045/br.2017.52.3.167
Lee, Kyu Ho, et al. "Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia." Blood research vol. 52,3 (2017): 167-173. doi: https://doi.org/10.5045/br.2017.52.3.167
Lee KH, Lim YT, Hah JO, Kim YK, Lee CH, Lee JM. Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia. Blood Res. 2017 Sep;52(3):167-173. doi: 10.5045/br.2017.52.3.167. Epub 2017 Sep 25. PMID: 29043231; PMCID: PMC5641508.
Copy Download .nbib Format: NLM
Identification and Antifungal Susceptibility Testing of .

Journal of global infectious diseases

Kaur R, Dhakad MS, Goyal R, Haque A, Mukhopadhyay G.
PMID: 27942193
J Glob Infect Dis. 2016 Oct-Dec;8(4):139-146. doi: 10.4103/0974-777X.192969.

CONCLUSION: The study confirmed the importance and reliability of conventional and molecular methods, and the acceptable agreements suggest Vitek-2 system an alternative method for speciation and sensitivity testing of Candida species infections.

Cite
Kaur R, Dhakad MS, Goyal R, et al. Identification and Antifungal Susceptibility Testing of . J Glob Infect Dis. 2016;8(4):139-146doi: 10.4103/0974-777X.192969.
Kaur, R., Dhakad, M. S., Goyal, R., Haque, A., & Mukhopadhyay, G. (2016). Identification and Antifungal Susceptibility Testing of . Journal of global infectious diseases, 8(4), 139-146. https://doi.org/10.4103/0974-777X.192969
Kaur, Ravinder, et al. "Identification and Antifungal Susceptibility Testing of ." Journal of global infectious diseases vol. 8,4 (2016): 139-146. doi: https://doi.org/10.4103/0974-777X.192969
Kaur R, Dhakad MS, Goyal R, Haque A, Mukhopadhyay G. Identification and Antifungal Susceptibility Testing of . J Glob Infect Dis. 2016 Oct-Dec;8(4):139-146. doi: 10.4103/0974-777X.192969. PMID: 27942193; PMCID: PMC5126752.
Copy Download .nbib Format: NLM
[Activity of amphotericin B and anidulafungin, alone and combined, against Candida tropicalis biofilms developed on Teflon.

Revista iberoamericana de micologia

Fernández-Rivero ME, Del Pozo JL, Valentín A, Fornes V, Molina de Diego A, Pemán J, Cantón E.
PMID: 28601403
Rev Iberoam Micol. 2017 Jul - Sep;34(3):175-179. doi: 10.1016/j.riam.2017.01.002. Epub 2017 Jun 16.

BACKGROUND: Current therapeutic strategies have a limited efficacy against Candida biofilms that form on the surfaces of biomedical devices. Few studies have evaluated the activity of antifungal agents against Candida tropicalis biofilms.OBJECTIVES: To evaluate the activity of amphotericin B...

Cite
Fernández-Rivero ME, Del Pozo JL, Valentín A, et al. Actividad de la anfotericina B y la anidulafungina, solas y combinadas, frente a biopelículas de Candida tropicalis formadas sobre Teflon [Activity of amphotericin B and anidulafungin, alone and combined, against Candida tropicalis biofilms developed on Teflon. Rev Iberoam Micol. 2017;34(3):175-179doi: 10.1016/j.riam.2017.01.002.
Fernández-Rivero, M. E., Del Pozo, J. L., Valentín, A., Fornes, V., Molina de Diego, A., Pemán, J., & Cantón, E. (2017). Actividad de la anfotericina B y la anidulafungina, solas y combinadas, frente a biopelículas de Candida tropicalis formadas sobre Teflon [Activity of amphotericin B and anidulafungin, alone and combined, against Candida tropicalis biofilms developed on Teflon. Revista iberoamericana de micologia, 34(3), 175-179. https://doi.org/10.1016/j.riam.2017.01.002
Fernández-Rivero, Marcelo Ernesto, et al. "Actividad de la anfotericina B y la anidulafungina, solas y combinadas, frente a biopelículas de Candida tropicalis formadas sobre Teflon" [Activity of amphotericin B and anidulafungin, alone and combined, against Candida tropicalis biofilms developed on Teflon. Revista iberoamericana de micologia vol. 34,3 (2017): 175-179. doi: https://doi.org/10.1016/j.riam.2017.01.002
Fernández-Rivero ME, Del Pozo JL, Valentín A, Fornes V, Molina de Diego A, Pemán J, Cantón E. Actividad de la anfotericina B y la anidulafungina, solas y combinadas, frente a biopelículas de Candida tropicalis formadas sobre Teflon [Activity of amphotericin B and anidulafungin, alone and combined, against Candida tropicalis biofilms developed on Teflon. Rev Iberoam Micol. 2017 Jul - Sep;34(3):175-179. doi: 10.1016/j.riam.2017.01.002. Epub 2017 Jun 16. Spanish. PMID: 28601403.
Copy Download .nbib Format: NLM
Modified ulcer debridement in the treatment of the superficial fungal infection of the cornea.

International journal of ophthalmology

Wang JY, Wang DQ, Qi XL, Cheng J, Xie LX.
PMID: 29487810
Int J Ophthalmol. 2018 Feb 18;11(2):223-229. doi: 10.18240/ijo.2018.02.07. eCollection 2018.

AIM: To evaluate the efficacy of modified corneal ulcer debridement in superficial fungal keratitis unresponsive to medications.METHODS: A total of 209 patients (209 eyes) with fungal keratitis, involving no more than 50% of the stromal depth and not responding...

Cite
Wang JY, Wang DQ, Qi XL, et al. Modified ulcer debridement in the treatment of the superficial fungal infection of the cornea. Int J Ophthalmol. 2018;11(2):223-229doi: 10.18240/ijo.2018.02.07.
Wang, J. Y., Wang, D. Q., Qi, X. L., Cheng, J., & Xie, L. X. (2018). Modified ulcer debridement in the treatment of the superficial fungal infection of the cornea. International journal of ophthalmology, 11(2), 223-229. https://doi.org/10.18240/ijo.2018.02.07
Wang, Jun-Yi, et al. "Modified ulcer debridement in the treatment of the superficial fungal infection of the cornea." International journal of ophthalmology vol. 11,2 (2018): 223-229. doi: https://doi.org/10.18240/ijo.2018.02.07
Wang JY, Wang DQ, Qi XL, Cheng J, Xie LX. Modified ulcer debridement in the treatment of the superficial fungal infection of the cornea. Int J Ophthalmol. 2018 Feb 18;11(2):223-229. doi: 10.18240/ijo.2018.02.07. eCollection 2018. PMID: 29487810; PMCID: PMC5824075.
Copy Download .nbib Format: NLM
Sweetgum: An ancient source of beneficial compounds with modern benefits.

Pharmacognosy reviews

Lingbeck JM, O'Bryan CA, Martin EM, Adams JP, Crandall PG.
PMID: 26009686
Pharmacogn Rev. 2015 Jan-Jun;9(17):1-11. doi: 10.4103/0973-7847.156307.

Sweetgum trees are large, deciduous trees found in Asia and North America. Sweetgum trees are important resources for medicinal and other beneficial compounds. Many of the medicinal properties of sweetgum are derived from the resinous sap that exudes when...

Cite
Lingbeck JM, O'Bryan CA, Martin EM, et al. Sweetgum: An ancient source of beneficial compounds with modern benefits. Pharmacogn Rev. 2015;9(17):1-11doi: 10.4103/0973-7847.156307.
Lingbeck, J. M., O'Bryan, C. A., Martin, E. M., Adams, J. P., & Crandall, P. G. (2015). Sweetgum: An ancient source of beneficial compounds with modern benefits. Pharmacognosy reviews, 9(17), 1-11. https://doi.org/10.4103/0973-7847.156307
Lingbeck, Jody M, et al. "Sweetgum: An ancient source of beneficial compounds with modern benefits." Pharmacognosy reviews vol. 9,17 (2015): 1-11. doi: https://doi.org/10.4103/0973-7847.156307
Lingbeck JM, O'Bryan CA, Martin EM, Adams JP, Crandall PG. Sweetgum: An ancient source of beneficial compounds with modern benefits. Pharmacogn Rev. 2015 Jan-Jun;9(17):1-11. doi: 10.4103/0973-7847.156307. PMID: 26009686; PMCID: PMC4441155.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1046 entries